Latest From BeiGene Ltd.
Imbruvica is keeping ahead of potential competitors in Europe by expanding its use in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia.
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
China saw a 150% increase in new drug approval applications in 2018, with oncology taking the lion's share of investigational new drug filings, notes a newly released annual report from China’s Center for Drug Evaluation. Meanwhile Darzalex has become the latest foreign drug to be approved.
Drug Discovery Tools
- Drug Discovery Tools
- In Vitro Diagnostics
- Therapeutic Areas
- BeiGene (Beijing) Co. Ltd.
- Parent & Subsidiaries
- BeiGene Ltd.
- Senior Management
John V Oyler, CEO
Howard Liang, PhD, CFO & Chief Strategy Officer
- Contact Info
Phone: 10 58958000
No. 30 Science Park Rd. Zhong-Guan-Cun
Life Science Pk
Changping District, 102206
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.